Ista Pharmaceuticals, Inc.

Allegro Pharmaceuticals, LLC

Advanced Corneal Systems

Other

Kato Pharmaceuticals, Inc.

Numoda Biotechnologies, Inc.

Jenius Pharma, LLC

Vicken H Karageozian

Hampar L Karageozian

John Y Park

Anthony B Nesburn

Gabriel Arturo Carpio Aragon

Maria Cristina Kenney

Jose Luis Gutierrez Flores

Michael John Mackel

David Castillejos

Jose L G Flores

Gabriel Arthuro Carpio Aragon

Phillip Baker

Jose Luis Gutierres Floress

Hamper Karageozian

Maria Christina Kenney

Peptide compounds and their use in treating diseases and disorders that cause, are caused by, or are characterized by cellular oxidative stress.

Treatments for diseases and disorders that involve oxidative stress

Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH&#x2014;CH(CH&#x2014;SOH)COOH or Arg-Gly-NH&#x2014;CH(CH&#x2014;SOH)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to &#x3b1;&#x3b2;-Integrin, &#x3b1;&#x3b2;-Integrin and &#x3b1;&#x3b2;-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

Peptide therapies for reduction of macular thickening

Peptides useable for treating cancer

Integrin receptor antagonists and their methods of use

Methods for treating disorders of the eye and/or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I as set forth herein. For ophthalmic applications, the compound may be delivered by intravitreal injection such that the compound causes vitreal liquefaction, posterior vitreoretinal detachment and other affects.

Treatment of ophthalmic disorders using urea

Methods and preparations for treating disorders of the eye and/or causing dissolution of corneal proteoglycans and organized healing of corneal stroma, softening of the cornea for non-surgical refractive correction of eyesight, removing corneal haze and opacification, inhibiting fibroblasts and preventing corneal fibrosis and scar formation, treating pterigiums and treating corneal neovascularization as well as iris neovascularization. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) antimetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, guanidinium chloride, guanidinium salts, thymidine, thymitadine, uradine, uracil, cysteine), reduced thioctic acid, uric acid, calcium acetyl salicylate, ammonium sulfate, isopropyl alcohol, ethanol, polyethylene glycol, polypropylene glycol or other compound capable of causing nonenzymatic dissolution of the corneal protoeglycans or f) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.

Agents for corneal or intrastromal administration to treat or prevent disorders of the eye

A thimerosal-free hyaluronidase preparation wherein the preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,000 MW. Also disclosed is a method for accelerating the clearance of hemorrhagic blood from the vitreous humor of the eye, said method comprising the step of contacting at least one hemorrhage-clearing enzyme (e.g., a &#x3b2;-glucuronidase, matrix metalloproteinase, chondroitinase, chondroitin sulfatase or protein kinase) with the vitreous humor in an amount which is effective to cause accelerated clearance of blood therefrom.

Hyaluronidase preparation for ophthalmic administration and enzymatic methods for accelerating clearance of hemorrhagic blood from the vitreous body of the eye

An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.

Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders

An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to the retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.

The invention provide a method for accelerating the clearance of hemorrhagic blood from the vitreous humor of a mammalian eye without producing toxicity to the eye, the method comprising contacting with the vitreous humor an amount of a solution which contains hyaluronidase to provide a dose of at least 1 International Unit of hyaluronidase, the hyaluronidase being in purified form possessing intravitreal hemorrhage-clearing activity and being free from impurities that produce toxicity to the eye.

Hyaluronidase preparation for ophthalmic administration and enzymatic methods for accelerating clearance of hemorrhagic blood from the vireous body of the eye

An Enzyme Orthokeratology method is provided for correcting refractive errors in the eye of a subject mammal. Accelerating reshaping of the cornea is accomplished by administering a corneal hardening amount of a corneal hardening agent to the eye of the subject. Reformation is accomplished under the influence of a rigid contact lens or a series of lenses having a concave curvature that will correct a refractive error. The cornea rapidly reshapes its convex curvature to the concave curvature of the contact lens, rendering the eye emmetropic. The cornea is permitted to &ldquo;harden&rdquo; to retain the new emmetropic shape. After &ldquo;hardening&rdquo; has occurred, the lens rendering the eye emmetropic is removed.

Use of corneal hardening agents in enzymeorthokeratology

A thimerosal-free hyaluronidase is prepared wherein the preferred hyaluronidase is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,000 MW. Also a method for accelerating the clearance of hemorrhagic blood from the vitreous humor of the eye is carried out by contacting at least one hemorrhage-clearing enzyme (e.g., hyaluronidase, .beta.-glucuronidase, matrix metalloproteinase, chondroitinase, chondroitin sulfatase or protein kinase) with the vitreous humor in an amount which is effective to cause accelerated clearance of blood therefrom.

Method for accelerating clearance of hemorrhagic blood from the vitreous

A thimerosal-free hyaluronidase preparation wherein the preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,000 MW. Also disclosed is a method for accelerating the clearance of hemorrhagic blood from the vitreous humor of the eye, comprising the step of contacting at least one hemorrhage-clearing enzyme (e.g., a .beta.-glucuronidase, matrix metalloproteinase, chondroitinase, chondroitin sulfatase or protein kinase) with the vitreous humor in an amount which is effective to cause accelerated clearance of blood therefrom.

An electrical power strip device generally including a) an elongate housing having at least one plug-receiving receptacle formed therein; b) a power supply cord extending from the housing and connectable to an electrical power source to deliver electrical current to said at least one plug receiving receptacle; c) a relay switch wired between said power supply cord and said at least one plug receiving receptacle such that, when said relay switch is closed power will flow from said power cord to said at least one plug receiving receptacle and when said relay switch is open power will not flow from said power cord to said at least one plug receiving receptacle; and, b) apparatus for communicating said relay switch to the primary device such that when the primary device is de-energized said relay switch will open so as to prevent power from reaching the secondary device(s) connected to said plug receiving receptacle(s) and when the primary device is energized the relay switch will close, thereby allowing electrical current from the power source to reach the secondary device(s) connected to the plug receiving receptacle(s) of the electrical power strip device.

Growing community of inventors

San Juan Capistrano, CA, United States of America

Vicken H Karageozian